PepBAN is introduced, a deep learning framework for modeling PepPI predictions that effectively learns the pattern of pairwise local interactions, enables the identification of key residues participating in the peptide-protein interactions, and offers an intuitive approach to interpret the underlying mechanisms of PepP...
Shuaiyan Li, Xiaorui Wang, Yuchen Zhu et al.· Journal of Chemical Informat...· 4 citations
EpiMII is presented, a Graph Neural Network model for MHC-II epitope design, which learns from the structural features of epitopes to predict their sequences, potentially contributing to vaccine development.
Jiayi Yuan, Xiaowei Xu, Ze-Yu Sun et al.· bioRxiv· 1 citation
This study established a unified model (NRIGN) based on the deep graphic architecture to discriminate agonists and antagonists targeting 26 successful or in-clinical-trial NR targets and achieves an excellent prediction accuracy and is robust enough to be applied in various real-world scenarios.
Kaimo Yang, Dejun Jiang, Qirui Deng et al.· Journal of Chemical Informat...· 2 citations
RAPiDock is presented, an all-atom diffusion model that predicts peptide–protein binding patterns across 92 amino acid types, enabling high-throughput virtual screening for advancing therapeutic peptide design and serve as a powerful tool for high-throughput virtual screening with structural precision.
A pioneering multi-modal framework with TCR-peptide-HLA sequence and structure features incorporating an attention mechanism designed to accurately identify tumor antigens with immunogenic properties, which presents a brand-new and promising approach for cancer immunotherapies that target tumor antigens.
Token-Mol is presented, a token-only 3D drug design model that encodes both 2D and 3D structural information, along with molecular properties, into discrete tokens, which introduces a Gaussian cross-entropy loss function tailored for regression tasks, enabling superior performance across multiple downstream application...
Ji-Ke Wang, Rui Qin, Mingyang Wang et al.· Nature Communications· 30 citations· ⚡1
AntiBMPNN consistently outperforms AbMPNN, AntiFold, and ProteinMPNN in designing complementarity determining regions (CDR) 1‐3, yielding stronger binding affinities and confirming its potential to improve therapeutic antibody design.
Ze-Yu Sun, Jiayi Yuan, Divya Jaiswal et al.· Advancement of science· 9 citations
The AI-guided development of a first-in-class proteolysis-targeting chimera (PROTAC) designed to selectively degrade the CLIP1-LTK fusion protein is reported, providing a promising therapeutic strategy for overcoming acquired resistance in kinase-driven cancers.
Shi-Cheng Chen, Hai-Ting Duan, S. Zhong et al.· Proceedings of the National...· 0 citations
BBBP-Atlas is proposed, a structure-aware BBB permeability prediction model designed for unified modeling of small molecules and peptides with the first cross-modal dataset OmniBBBP, which offers a versatile and cross-modal approach for single-compound prediction, batch screening, and dataset exploration for CNS drug d...
Xin Shen, Qun Su, Hao Luo et al.· bioRxiv· 0 citations
The Comprehensive VS Platform with AI Engine (CVSP-AIE) for drug discovery from compound libraries integrates three AI models: KarmaDock, a fast docking model that directly updates atomic coordinates; CarsiDock, an accurate docking model that predicts protein-ligand distances and reconstructs binding poses; and RTMScor...
